New development and update on China Bioanalysis Forum.

This article provides an update on new development of China Bioanalysis Forum (CBF). CBF became a member association of Chinese Pharmaceutical Association (CPA) at the end of 2019. The official ceremony and first scientific symposium were held in Shanghai on 18 September 2020. The president of Chinese Pharmaceutical Association and representatives from industry, Contract Research Organization (CRO), hospitals and academic institutes attended the ceremony. Seven experts in the field gave presentations on various topics including Drug Metabolism and Pharmacokinetics (DMPK) and bioanalytical support in drug discovery and development as well as experience in Traditional Chinese Medicine research. With the continuous growth of research and development in China, it is well acknowledged that bioanalysis provides critical support for new innovative medicines and generic drug development in the region.

The 7th China Bioanalysis Forum Annual Meeting.

This article summarizes the highlights from the 7th China Bioanalysis Forum (CBF) Annual Conference in June 2019. The annual CBF conference provided a great platform for the Chinese bioanalytical community to discuss the current bioanalytical regulations, share challenges and experiences. With rapid growth of the pharma industry in China in the past decade and advancement in regulatory reform, the overall science and quality of regulated bioanalysis have now reached international standards. The CBF continues its efforts in promoting scientific excellence, quality and regulatory compliance in China and facilitating close collaboration with the international bioanalysis community.